Currently, several molecular alterations characteristic of GBM are known, related to dysregulation in the receptor tyrosine kinases (RTKs)/Ras/phosphatidylinositol 3-kinase (PI3K) pathway, which is altered in 88% of patients, with overexpression of EGFR, PDGFR, and VEGFR. The gene discussed is KDR; the disease is glioblastoma.